
Monday, September 10, 2018 4:48:49 PM

Liked By
Spread the love. Be the first to like this post!
Recent HUGE News
- FSD Pharma (Symbol: HUGE) Renews Shareholder Intelligence Services to Investigate Possible Naked Short Selling and Appeals to The Regulators and Oversight Bodies to Look Into The Short Selling Activity Of Its Stock • Business Wire • 03/14/2023 12:30:00 PM
- InvestmentPitch Media Video Discusses FSD Pharma’s Addition of Kevin Harrington, Author, “Shark Tank” Original, and Infomercial Pioneer to its Advisory Board • GlobeNewswire Inc. • 03/01/2023 11:00:00 AM
- Original “Shark” and Iconic Entrepreneur Kevin Harrington Joins FSD Pharma Advisory Board • Business Wire • 02/28/2023 01:30:00 PM
- FSD Pharma Presenting Two Scientific Posters on Preclinical Toxicology and Efficacy Data of Lucid-21-302 (Lucid-MS) at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2023 Forum • Business Wire • 02/21/2023 07:30:00 AM
- FSD Pharma Regains Compliance with NASDAQ Continued Listing Requirements • Business Wire • 02/15/2023 12:30:00 PM
- FSD Pharma Launches A New Research and Development Program Targeting Unmet Medical Needs for Alcohol Misuse • Business Wire • 02/14/2023 07:30:00 AM
- InvestmentPitch Media Video Discusses FSD Pharma’s Receipt of No Objection Letter from Health Canada for Clinical Trials for LUCID-21-302 for MS • GlobeNewswire Inc. • 02/09/2023 11:00:00 AM
- FSD Pharma Receives Regulatory Clearance for Its Proposed Phase-1 Clinical Trial of Lucid-21-302 (Lucid-MS), First-in-Class Multiple Sclerosis Drug Candidate • Business Wire • 02/07/2023 01:30:00 PM
- Recruiting Underway in FSD Pharma’s Phase 2 Trial of FSD-PEA (FSD201) for the Treatment of Chronic Pain Associated With Idiopathic MCAS (MCAD) • Business Wire • 01/30/2023 01:30:00 PM
- InvestmentPitch Media Video Discusses FSD Pharma’s Submission of its Clinical Trial Application for Planned Phase-1 Trial for Lucid-MS, a Candidate for Treatment of MS • GlobeNewswire Inc. • 01/19/2023 11:00:00 AM
- FSD Pharma submits its phase-1 Clinical Trial Application for Lucid-MS (Lucid-21-302) for first-in-human safety and tolerability investigation • Business Wire • 01/17/2023 01:30:00 PM
- FSD Pharma Announces Share Repurchase Program • Business Wire • 01/13/2023 01:30:00 PM
- FSD Pharma Inc Incorporates New Subsidiary to Capitalize on Drug Development Incentives in Australia • Business Wire • 01/09/2023 01:30:00 PM
- FSD Pharma to Attend 41st Annual J.P. Morgan Healthcare Conference 2023 • Business Wire • 01/06/2023 01:30:00 PM
- FSD Pharma Announces Changes to the Board of Directors • Business Wire • 11/28/2022 09:30:00 PM
- InvestmentPitch Media Video Discusses FSD Pharma’s Announcement that the Claim for US$30.2 Million Brought by Dr. Raza Bokhari, the Company’s Former CEO, has been Dismissed in its Entirety • GlobeNewswire Inc. • 11/15/2022 11:00:00 AM
- FSD Pharma Announces Arbitrator Dismisses Claims by Former CEO, Dr. Raza Bokhari • Business Wire • 11/10/2022 02:00:00 PM
- FSD Pharma Inc. Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency • Business Wire • 09/29/2022 12:30:00 PM
- FSD Pharma Participating in H.C. Wainwright 24th Annual Global Investment Conference, On-Demand Presentation Available • Business Wire • 09/12/2022 12:30:00 PM
- FDA and Health Canada Clear IND for FSD Pharma to Proceed with Phase 2 Trial of FSD201 for Nociplastic Pain Associated with Idiopathic Mast Cell Activation Syndrome • Business Wire • 09/06/2022 12:30:00 PM
- FSD Pharma Subsidiary Lucid Psycheceuticals Files for Patent On Novel Formulations of Palmitoylethanolamide, Presents Preclinical Toxicology Results at an International Symposium • Business Wire • 07/13/2022 12:30:00 PM
- FSD Pharma Inc. Announces Results of Annual General Meeting of Shareholders And Other Corporate Updates • Business Wire • 06/27/2022 12:30:00 PM
- InvestmentPitch Media Video Discusses FSD Pharma’s Submission of an Investigational New Drug or “IND” Application with the U.S. Food and Drug Administration and Health Canada for Treatment of a Yet-To-Be-Disclosed Inflammatory Disorder • GlobeNewswire Inc. • 06/01/2022 10:00:00 AM
- FSD Pharma Files Investigational New Drug Application (“IND”) with FDA and Health Canada for Phase-2 Trial of FSD-201 for an Inflammatory disorder and Provides Corporate Updates • Business Wire • 05/31/2022 12:30:00 PM
- FSD Pharma Issues Circular, Adopts Incentive Plan and Grants PSUs • Business Wire • 05/24/2022 12:30:00 PM
FEATURED Predictmedix Announces US Patent Grant for AI-Powered Impairment Detection Technology for Cannabis and Alcohol Screening • Mar 21, 2023 7:56 AM
HealthLynked Corp. Awarded Patent 11,600,395 for "Secure Patient Access via Healthcare Service Provider Specific Wireless Access Point" • HLYK • Mar 21, 2023 8:00 AM
Hollywall Entertainment, Inc. (HWAL) forms new Technology Division • HWAL • Mar 20, 2023 12:50 PM
Thunder Energies Retains Global IR Firm • TNRG • Mar 20, 2023 9:30 AM
Tudor Gold Announces Significant Upgrade to Mineral Resource Estimate for the Goldstorm Porphyry Deposit..... • TUD • Mar 16, 2023 11:56 AM
Golden Matrix Reports First Quarter Financial Results With Record Revenues of $10.78 Million • GMGI • Mar 16, 2023 9:24 AM